Contract Research Organisation hVIVO plc (AIM: HVO), a company that specialises in human challenge clinical trials, on Wednesday announced positive results from a Phase 2a trial conducted for Shionogi & Co Ltd. The study evaluated the investigational oral RSV antiviral candidate S-337395, which holds Fast Track designation from the US FDA.

The randomised, placebo-controlled, double-blind trial, conducted using healthy volunteers recruited through FluCamp, demonstrated an 88.94% reduction in viral load at the highest dose (P